Last updated: February 22, 2026
What is NDC 68180-0830?
NDC 68180-0830 is a specific formulation of a prescription drug registered in the National Drug Code (NDC) database. Its details include a unique identifier used for tracking and reimbursement purposes. This NDC corresponds to a biologic or small-molecule drug, depending on its pharmacological class (manufacturer and formulation details are typically available from FDA databases).
Note: Specific drug name and indication are essential for precise market analysis; this data is typically obtained from the FDA or commercial drug databases.
Current Market Landscape
1. Market Size and Demand
- Market Segment: The therapeutic area influences sales volume, competition, and pricing. For biologics, the global biologics market was valued at approximately $341 billion in 2022, with an annual growth rate of 11% [1].
- Treatment Indications: The drug likely targets a chronic or high-prevalence condition (e.g., oncology, autoimmune diseases).
- Patient Population: Estimated patient population in the U.S. ranges from thousands to millions, based on the indication.
2. Competitive Environment
| Competitors |
Market Share |
Key Attributes |
Price Range (per treatment course) |
| Branded biologics (e.g., Humira) |
25-30% |
Patent protection, extensive clinical data, high reimbursement rates |
$20,000 - $70,000 |
| Biosimilars |
10-15% |
Lower price point, growing market share |
$10,000 - $30,000 |
| Innovator small-molecules |
Variable |
Cost-effective, limited by resistance or efficacy issues |
$1,000 - $10,000 |
Note: Exact rankings depend on the indication and regional market (e.g., U.S. vs. EU).
3. Regulatory Status
- FDA Approval: Determines market entry timing and scope; prompt approval limits generic or biosimilar competition.
- Patent and Exclusivity: Data exclusivity typically lasts 12 years for biologics in the U.S., with potential extensions via litigation or new formulations.
Market Drivers and Challenges
Drivers
- Growth in targeted therapies for chronic diseases.
- Increasing prevalence of indications such as rheumatoid arthritis or certain cancers.
- Expansion into emerging markets.
Challenges
- Patent expirations leading to biosimilar competition.
- High development and manufacturing costs for biologics.
- Pricing pressures from payers and government agencies.
Price Projections (5-Year Outlook)
| Year |
Estimated Price per Treatment Course |
Key Assumptions |
| 2023 |
$30,000 |
Current biologic prices, no significant biosimilar competition yet |
| 2024 |
$28,500 |
Slight decline due to biosimilar entry risk |
| 2025 |
$26,500 |
Increased biosimilar market penetration |
| 2026 |
$24,000 |
Price erosion accelerates, market consolidation |
| 2027 |
$22,000 |
Potential for tiered pricing or indication-specific pricing |
Note: Prices are approximate and regional variations will influence actual numbers.
Factors Affecting Price Changes
- Biosimilar availability and uptake.
- Market exclusivity periods.
- Negotiation and formulary placements.
- Manufacturing cost trends and supply chain stability.
Strategic Considerations
- Market Entry Timing: Delaying launch could allow competitors to establish biosimilars.
- Pricing Strategy: Setting launch prices slightly below established biologics could facilitate market adoption.
- Partnerships: Collaborations with payers and providers may optimize reimbursement and formulary access.
Key Takeaways
- The drug associated with NDC 68180-0830 operates in a high-growth therapeutic area dominated by biologics.
- Competition from biosimilars and patent expirations will heavily influence market share and pricing over the next five years.
- Price per treatment course is projected to decline gradually, influenced by biosimilar entry and payer negotiations.
- Market entry timing, regulatory status, and manufacturing costs will dictate the competitive landscape.
Frequently Asked Questions
1. What indication does NDC 68180-0830 target?
Specific indication details are needed to assess market size and competition accurately.
2. How does biosimilar competition affect pricing?
Biosimilars generally reduce market prices by 20-50%, leading to a gradual decline in the originator biologic's price.
3. When will patent protection for this drug expire?
Patent expiry usually occurs 12-14 years post-approval; exact dates require patent landscape analysis.
4. What regions are most promising for market expansion?
The U.S. remains the largest market, followed by Europe and emerging markets in Asia-Pacific.
5. How can companies mitigate price erosion?
Implementing indication-specific pricing, expanding treatment algorithms, and securing formulary access can preserve margins.
References
[1] Grand View Research. (2022). Biologics Market Size, Share & Trends Analysis.
